Clinical Study to Monitor Plasma Levels of 24OHC in Subject With HD

Huntington Disease Clinical Trial

— Chol-HD  

Official title:

Innovative Therapeutic Strategy Targeting Neurons With Cholesterol in Huntington Disease: From Preclinical Studies to Clinical Trial Readiness

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04257513
• Other study ID #: Chol-HD
• Status: Recruiting
• Start date: October 1, 2019
• Est. completion date: September 2022

Study information

• Verified date: February 2021
• Source: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
• Contact: Caterina Mariotti, MD
• Phone: +39022394
• Email: caterina.mariotti[@]istituto-besta.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A 2-year clinical longitudinal study to measure plasma concentrations of 24S-hydroxycholesterol, a brain-derived cholesterol catabolite, in subjects with Huntington disease, from the presymptomatic to the symptomatic stages.

Description:

In cross-sectional studies, the plasma level of brain-derived 24S-hydroxycholesterol (24OHC) has been found to be significantly diminished in HD patients from the first stages of the disease. Furthermore, in HD gene-positive pre-symptomatic (pre-HD) the plasma levels can predict the development of motor signs of disease in subjects closer to onset, better than in subjects far from onset. These data suggest that circulating 24OHC might be a candidate biomarker for phenotypic conversion and for disease progression in different stages of the disease.

Detailed neurological, cognitive and imaging data and blood samples will be collected at baseline, and after two years to investigate the rate of changes along the longitudinal study. Isotope dilution mass spectrometry (assay performed at Istituto di Ricerche Farmacologiche Mario Negri IRCCS) will be used to measure the plasma levels of brain-derived 24OHC and other sterols reflecting peripheral cholesterol synthesis. The investigators expect to establish whether changes in plasma 24OHC mark disease progression and, eventually, phenoconversion from pre-symptomatic to symptomatic stages in combination with clinical, cognitive and imaging parameters.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: September 2022
• Est. primary completion date: September 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Symptomatic HD subjects

1. Age = 18 years

2. Known family history of HD and genetically confirmed disease by direct DNA test (CAG expansion > 35 repeats)

3. Clinical diagnostic motor features of HD, defined as score> 5 at the motor Unified Huntington Disease Rating Scale (mUHDRS)

4. Stage I or II or III HD, defined as UHDRS Total Functional Capacity (TFC) scores between 3 and 13 inclusive (Marder, 2000)

Presymptomatic HD subjects

1. Age = 18 years

2. Known family history of HD and genetically confirmed mutation by direct DNA test (CAG expansion > 35 repeats)

3. Absence of clinical motor features of HD, defined as mUHDRS rating scale = 5

Healthy Subjects

1. Age = 18 years

2. Absence of known family history of HD or genetically confirmed negative DNA test for HD (CAG expansion = 35 repeats)

3. Absence of clinical motor features of HD, defined as mUHDRS rating scale = 5

Exclusion Criteria:

1. Participation in clinical pharmacological trials

2. Inability to undergo and tolerate MRI scans (e.g. claustrophobia, severe chorea, MRI-incompatible intrauterine devices, metal implants, ect)

3. Inability or unwillingness to undertake any of the study procedures

Related Conditions & MeSH terms

• Huntington Disease

Intervention

Diagnostic Test:
• Brain MRI
Neurological and Cognitive evaluation; Brain MRI

Locations

Country	Name	City	State
Italy	UOC Genetica Medica e Neurogenetica	Milano

Sponsors (2)

Lead Sponsor	Collaborator
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	Istituto Di Ricerche Farmacologiche Mario Negri

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	plasmatic 24OHC levels	Changes in plasmatic 24OHC levels measured	at baseline and after 2-years follow up visit
Secondary	Changes in the score of the Unified Huntington Disease Rating Scale (UHDRS)	The concentration of 24OHC will be correlated with clinical evaluation to the stage of the disease and its progression.	after 2-years follow up visit
Secondary	Changes in score at the Digit Symbol Modalities Test (DSMT)	The concentration of 24OHC will be correlated with cognitive evaluation to the stage of the disease and its progression.	after 2-years follow up visit
Secondary	Changes in caudate nucleus volume measured at MRI	The concentration of 24OHC will be correlated with Imaging the stage of the disease and its progression.	after 2-years follow up visit